摘要
目的评价回生口服液对中晚期非小细胞肺癌(NSCLC)患者化疗后血凝状态及疗效的影响。方法将69例首次确诊且可接受化疗的中晚期NSCLC随机分为实验组35例和对照组34例,两组皆采用含铂三代一线方案(吉西他滨+顺铂,或多烯紫杉醇+顺铂)化疗,21天为一周期。其中实验组在化疗同时配合使用回生口服液,10毫升/次,3次/日,从化疗当天开始口服,全程使用直至化疗终止。所有患者至少接受2周期化疗并评价临床客观疗效,在化疗前和第二周期化疗结束后一周检测血小板(PLT)、D-二聚体(D-dimer)、纤维蛋白水平(FIB)。结果实验组总有效率74.3%(26/35),临床受益率(CBR)为80.0%(28/35),疾病进展时间(TTP)为(5.5±2.8)月,平均生存期为(11.1±5.8)月。对照组总有效率47.1%(16/34),CBR为55.9%(20/34),TTP为(4.2±2.5)月,平均生存期为(8.4±5.3)月,两组总有效率、CBR、TTP与平均生存期比较差异均有统计学意义(P<0.05);化疗后实验组PLT(157±89)×109/L、D-dimer(2078±770)μg/ml、FIB(3.8±1.4)g/L,与对照组PLT(208±118)×109/L、D-dimer(2680±980)μg/ml、FIB(4.6±1.8)g/L比较差异均有统计学意义(P<0.05、P<0.01、P<0.05),且对照组化疗后有3例(8.8%)发生深静脉血栓,实验组无1例发生。结论回生口服液配合化疗提高了NSCLC患者近期疗效,并在一定程度上改善了血液高凝状态,可预防深静脉血栓的发生,并能延长TTP和平均生存期,值得临床推广。
Objective To evaluate the effect of Huishengkoufuye on treatment and blood coagulation state in patients with Mid-advanced non-small cell lung cancer（NSCLC） after chemotherapy.Methods Sixty-nine untreated patients confirmed by pathological examination were randomly divided into two groups.Thirty-five patients in experimental group received the third generation platinum-based chemotherapy as first-line treatment（GEM＋DDP or TXT＋DDP）combined with Huishengkoufuye（10ml every time,third-daily）.Thirty-four patients in control group received chemotherapy only.Treatment was repeated every 21 days.The objective curative effect of the two groups were compared after two cycles at least.The PLT,D-dimer and Fib were determined pre and post treatment.Results In the experimental group and the control group： The overall response rates were 74.3 %（26/35） and 47.1 %（16/34） respectively.The CBR rates were 80.0 %（28/35） and 55.9 %（20/34） respectively.The TTP were（5.5±2.8）months and（4.2±2.5）respectively.The mean survival time were（11.1±5.8）months and（8.4±5.3）months respectively.The experimental group was superior to the control group in the overall response rate,CBR,TTP and mean survival time,with significant differences（P0.05）.The PLT,D-dimer and Fib after treatment were（157±89）×109/L,（2078±770） μg/ml,（3.8±1.4）g/L and（208±118）×109/L,（2680±980） μg/ml,（4.6±1.8） g/L respectively（P0.05,P0.01,P0.05）.Moreover,3（8.8%）patients occurred deep venous thrombosis（DVT） in the control group,but no case in the experimental group.Conclusion These results suggest that Huishengkoufuye combined with chemotherapy can enhance the treatment effect and improve blood hypercoagulable state with prevent deep venous thrombosis,which is helpful to receive a high clinical benefit response,extend TTP and mean survival time.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2011年第6期695-697,700,共4页
Cancer Research on Prevention and Treatment
基金
湖北省卫生厅科研资助项目(JX4B52)
